Van Hulzen Asset Management LLC bought a new position in Stryker Corporation (NYSE:SYK - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,148 shares of the medical technology company's stock, valued at approximately $4,769,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of SYK. Gables Capital Management Inc. acquired a new stake in shares of Stryker during the 2nd quarter worth approximately $25,000. Kilter Group LLC bought a new position in shares of Stryker during the 2nd quarter worth about $25,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the 4th quarter valued at about $26,000. Sankala Group LLC acquired a new stake in shares of Stryker in the 4th quarter valued at about $26,000. Finally, Compass Financial Management LLC bought a new stake in Stryker in the 2nd quarter valued at about $27,000. 77.09% of the stock is currently owned by institutional investors.
Stryker Price Performance
SYK stock opened at $327.80 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The business has a 50-day simple moving average of $327.39 and a two-hundred day simple moving average of $332.16. The company has a market capitalization of $125.73 billion, a P/E ratio of 33.97, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.
Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.
Stryker Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker's dividend payout ratio (DPR) is 36.48%.
Analyst Ratings Changes
SYK has been the topic of several recent research reports. Raymond James Financial set a $370.00 price target on Stryker in a report on Friday, July 31st. Truist Financial upped their target price on Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research report on Friday, July 31st. Sanford C. Bernstein set a $410.00 target price on Stryker in a report on Friday, May 1st. Royal Bank Of Canada reduced their price target on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Finally, Leerink Partners decreased their price target on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating for the company in a research note on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $386.28.
Check Out Our Latest Stock Analysis on Stryker
Insider Buying and Selling at Stryker
In other news, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm's stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 355,370 shares of company stock worth $119,447,201. Corporate insiders own 4.60% of the company's stock.
Stryker Company Profile
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Read More
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
